185 related articles for article (PubMed ID: 35977347)
1. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma.
Wang JR; Montierth M; Xu L; Goswami M; Zhao X; Cote G; Wang W; Iyer P; Dadu R; Busaidy NL; Lai SY; Gross ND; Ferrarotto R; Lu C; Gunn GB; Williams MD; Routbort M; Zafereo ME; Cabanillas ME
JCO Precis Oncol; 2022 Aug; 6():e2100504. PubMed ID: 35977347
[TBL] [Abstract][Full Text] [Related]
2. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
3. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract][Full Text] [Related]
4. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
Kunstman JW; Juhlin CC; Goh G; Brown TC; Stenman A; Healy JM; Rubinstein JC; Choi M; Kiss N; Nelson-Williams C; Mane S; Rimm DL; Prasad ML; Höög A; Zedenius J; Larsson C; Korah R; Lifton RP; Carling T
Hum Mol Genet; 2015 Apr; 24(8):2318-29. PubMed ID: 25576899
[TBL] [Abstract][Full Text] [Related]
7. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF
Zhao X; Wang JR; Dadu R; Busaidy NL; Xu L; Learned KO; Chasen NN; Vu T; Maniakas A; Eguia AA; Diersing J; Gross ND; Goepfert R; Lai SY; Hofmann MC; Ferrarotto R; Lu C; Gunn GB; Spiotto MT; Subbiah V; Williams MD; Cabanillas ME; Zafereo ME
Thyroid; 2023 Apr; 33(4):484-491. PubMed ID: 36762947
[No Abstract] [Full Text] [Related]
8. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
[No Abstract] [Full Text] [Related]
10. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
11. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
Romei C; Elisei R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
[TBL] [Abstract][Full Text] [Related]
12. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
[TBL] [Abstract][Full Text] [Related]
13. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
14. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Xing M; Liu R; Liu X; Murugan AK; Zhu G; Zeiger MA; Pai S; Bishop J
J Clin Oncol; 2014 Sep; 32(25):2718-26. PubMed ID: 25024077
[TBL] [Abstract][Full Text] [Related]
16. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
[TBL] [Abstract][Full Text] [Related]
17. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M
J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
[TBL] [Abstract][Full Text] [Related]
18. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
19. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
da Silva TN; Rodrigues R; Saramago A; Pires C; Rito M; Horta M; Martins C; Leite V; Cavaco BM
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651156
[TBL] [Abstract][Full Text] [Related]
20. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
[Next] [New Search]
